DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for pyoderma gangrenosum — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePyoderma gangrenosum maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pyoderma gangrenosum is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
elastase, neutrophil expressed (ELANE) — ELANE is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7CBK · 2.7 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
In a retrospective Australian review of 29 patients with pyoderma gangrenosum over ten years, nearly all received immunosuppressant therapy, 10 (35%) underwent surgery, and 8 (28%) received hyperbaric oxygen therapy. At discharge, 21 (72%) patients’ ulcers had improved, but there were 4 (14%) inpatient deaths. At six months, only 3 of 10 cases with available follow-up showed complete ulcer healing. Complications from medical therapy occurred in 23 of 35 admissions (66%), most commonly poor blood sugar control in diabetics (6 patients, 17%) and steroid-induced diabetes (5 patients, 14%). Among the 10 patients who had surgery, 8 (80%) had ulcers that were healed or improved at six months; all 3 who received split skin grafting under immunosuppressive cover, two with hyperbaric oxygen, had no graft failure or pathergy.
A separate case report describes a 27-year-old pregnant nurse whose pretibial wound after a fall was mistaken for necrotising fasciitis and treated with multiple debridements, which worsened the condition. Once pyoderma gangrenosum was suspected, corticosteroids were started and were successful. The authors note that mistreatment of pyoderma can lead to disfigurement.
Another case report describes a 68-year-old woman whose pyoderma gangrenosum first appeared around 30 years earlier during an exacerbation of rheumatoid arthritis and recurred as a manifestation of locally advanced breast cancer. Standard anti-inflammatory therapy was unsuccessful; the skin ulceration healed only after effective endocrine cancer therapy. The authors conclude that pyoderma gangrenosum has a recurrent nature and may be reactivated by various causes, requiring treatment of the underlying disease.
What remains missing are prospective trials with standardised outcome measures, larger patient cohorts to allow subgroup analyses, and any controlled data on the optimal timing or combination of surgery, immunosuppression, and hyperbaric oxygen. No randomised comparisons of different immunosuppressive regimens exist, and the role of targeted therapies in refractory or paraneoplastic cases is unexplored.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Plastic Surgery · 2013 · 40 citations
Inpatient Management of Pyoderma Gangrenosum
AbstractBACKGROUND: Pyoderma gangrenosum (PG) is a rare, ulcerative neutrophilic skin condition of unknown etiology. The disease continues to pose therapeutic challenges, with ongoing controversy regarding the role of surgery. METHODS: A retrospective medical records review was conducted for 29 patients who were diagnosed and treated for PG at an Australian tertiary center over 10 years, from 1 January 2000 to 31 December 2010. RESULTS: A total of 29 patients had a diagnosis of PG, with a total of 35 admissions. Nearly all patients had immunosuppressant therapy and 10 (35%) patients underwent surgery. Eight (28%) received hyperbaric oxygen therapy. Complications secondary to medical therapy occurred in 23 (66%) of admissions, with the commonest being poor blood sugar control in patients with diabetes (n = 6, 17%) and steroid-induced diabetes (n = 5, 14%). At discharge, 21 (72%) patients' ulcers had improved and there were 4 (14%) inpatient deaths. At 6 months, 3 of 10 cases with available follow-up showed complete ulcer healing. Most of the patients (n = 8, 80%) who underwent combined medical and surgical therapy had ulcers that had either completely healed or improved at 6 months after discharge. All 3 patients who underwent split skin grafting under immunosuppressive cover (with 2 having hyperbaric oxygen therapy) had no postoperative graft failure or pathergy. CONCLUSIONS: Pyoderma gangrenosum remains a therapeutic challenge, with significant complications and morbidity from long-term medical treatment. Surgery should be considered in conjunction with combined hyperbaric and immunosuppressive therapy once the disease is quiescent, to reduce disease-related comorbidity as well as the consequent adverse effects of long-term immunosuppressant therapy.
Pyoderma Gangrenosum after Minor Trauma in a Pregnant Woman, Mistaken for Necrotizing Fasciitis: Report of a Case and Literature Review
AbstractBACKGROUND: Pyoderma gangrenosum is an ulcerative, non-infectious skin disorder. However, it can be mistaken as necrotizing fasciitis, a life-threatening infective condition. We describe here a case of pyoderma gangrenosum after minor trauma treated as necrotizing fasciitis. METHODS: Case report and literature review. CASE REPORT: A 27-year-old pregnant nurse had a pretibial wound after a fall on a rough surface. When erythema developed and no response to empirical antibiotic therapy was observed, multiple debridements were performed. Paradoxically, her condition became worse. The diagnosis of pyoderma gangrenosum was suspected. Treatment with corticosteroids was started and this was successful. CONCLUSION: Pyoderma gangrenosum can mimic infectious necrotizing fasciitis. Differentiating these two conditions is important because mistreatment of pyoderma can lead to disfigurement.
Journal of Medical Case Reports · 2014 · 15 citations · open access
Recurrent pyoderma gangrenosum precipitated by breast cancer: a case report and review of the literature
AbstractINTRODUCTION: Pyoderma gangrenosum is a rare clinical entity of poorly understood pathogenesis, characterized by rapidly progressing skin necrosis. In around half of patients pyoderma gangrenosum is a manifestation of underlying systemic diseases, such as rheumatoid arthritis, inflammatory bowel disease or myeloproliferative disorders. There have been very few reports on the association of pyoderma gangrenosum with solid malignancies. CASE PRESENTATION: We report a case of a 68-year-old Caucasian woman in whom pyoderma gangrenosum first appeared around 30 years earlier, at the time of exacerbation of rheumatoid arthritis, and recurred as a manifestation of locally advanced breast cancer. The causative role of the neoplastic process was partly confirmed by the healing of the skin ulceration only following effective endocrine cancer therapy, whereas earlier attempts with standard anti-inflammatory therapy were unsuccessful. CONCLUSIONS: Pyoderma gangrenosum has a recurrent nature and may be reactivated by various causes within several years. Therefore, a prompt and thorough diagnosis accompanied by treatment of the underlying disease is necessary.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
